Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, FDA, PLW

Phanes Therapeutics' anti-claudin 18.2 antibody patent granted in the US


SAN DIEGO, Jan. 17, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent (Patent No. US 11,555,070) for its anti-claudin 18.2 antibodies.

The patent relates to the invention of anti-claudin 18.2 monoclonal antibodies and bispecific antibodies comprising an anti-claudin 18.2 arm, which includes Phanes' first-in-class bispecific antibody, PT886, an anti-claudin 18.2/anti-CD47 bispecific antibody being developed for gastric and pancreatic cancers. Phanes has received clearance from the US FDA to commence Phase I studies with PT886 in June 2022. PT886 has also been granted orphan drug designation from the FDA in June 2022 for the treatment of pancreatic cancer.

"This is the seventh Phanes patent granted in the US and the tenth patent granted worldwide," said Dr. Ming Wang, PhD, MBA, Founder and CEO of Phanes Therapeutics. "As Phanes expands from a research stage to a clinical stage organization, we expect to have additional patent applications issued, further strengthening the intellectual property portfolio and competitiveness of our pipeline."

About Phanes Therapeutics
Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it has three assets at clinical stage, including its best-in-class monoclonal antibody (mAb) program, PT199, and two first-in-class bispecific antibody programs, PT886 and PT217. Both PT886 and PT217 have been granted orphan drug designation by FDA. Its pipeline also includes humanized mAbs, biparatopics, and single-chain variable fragments (scFvs) against multiple tumor-associated antigens (TAAs) that are suitable for ADC and CAR-T applications, respectively.

The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbodyTM, SPECpairTM and ATACCbodyTM to develop novel biologics that address high unmet medical needs in cancer. PACbodyTM is a proprietary approach for constructing bispecific antibodies without using protein engineering so that the antibody molecules maintain native structures with superb CMC characteristics, SPECpairTM allows mAb-like manufacturability of bispecific antibodies with native IgG-like structures, and ATACCbodyTM is a technology for targeting solid tumors using immuno-oncology molecules with modulated activities designed to minimize the risk of cytokine release syndrome.

For more information about Phanes Therapeutics, please visit www.phanesthera.com.
For business development or media inquiries please contact [email protected] or [email protected], respectively.

SOURCE Phanes Therapeutics


These press releases may also interest you

at 13:30
Waterfield Tech, a leading global customer engagement solutions provider, today announced its new suite of generative AI solutions. This innovative offering enables contact center leaders to build on the promise of AI in their organizations with low...

at 13:30
The "Global Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook) - Q1 2024 Update" report has been added to ResearchAndMarkets.com's offering. Global gift card industry is expected to grow by 7.9% on annual basis to...

at 13:20
Coalition, the world's first Active Insurance provider designed to prevent digital risk before it strikes, today announced that Coalition Insurance Company (CIC), the full-stack Active Cyber Insurance carrier, is now open for quoting Coalition's...

at 13:20
Blumira, a leading security and operations platform, today announced tech industry veteran Haiyang Li has joined the company as its vice president of engineering, effective March 18. Li joins the Blumira leadership team with extensive experience...

at 13:16
Risas Dental & Braces ("Risas"), a dental and braces provider that serves patients in Arizona, Colorado, Texas, and Nevada, has learned of a data security incident that may have involved the protected health information of certain Risas patients....

at 13:15
The "Long-Acting Drug Delivery Technologies and Services Market: A Global and Regional Analysis, 2023-2033" report has been added to ResearchAndMarkets.com's offering. As of 2022, the global long-acting drug delivery technologies and services...



News published on and distributed by: